IGI Logo

Aurobindo Pharma is currently trading at Rs. 442.50, up by 1.30 points or 0.29% from its previous closing of Rs. 441.20 on the BSE.

The scrip opened at Rs. 444.75 and has touched a high and low of Rs. 445.00 and Rs. 440.10 respectively. So far 17669 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 742.25 on 11-Jan-2022 and a 52 week low of Rs. 429.30 on 02-Jan-2023.

Last one week high and low of the scrip stood at Rs. 447.25 and Rs. 429.30 respectively. The current market cap of the company is Rs. 26021.53 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 37.97% and 10.20% respectively.

Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Azacitidine for Injection, 100 mg Single-Dose Vial. Azacitidine for Injection, 100 mg Single-Dose Vial, to be bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Vidaza for Injection, 100 mg Single-Dose Vial, of Bristol-Myers Squibb Company. The product is expected to be launched by this month. The approved product has an estimated market size of around $46 million for the twelve months ending November 2022, according to IQVIA.

This is the 153rd ANDA (including 10 tentative approvals received) out of Eugia Pharma Speciality Group (EPSG) facilities, manufacturing both oral and sterile specialty products

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.